Mentions
Extended reach
Total likes
Video views
AI synopsis
The overall discussions show strong support for the publication's conclusions, as many posts reiterate key findings such as finerenone reducing cardiovascular outcomes regardless of prior CVD, with words like 'benefits,' 'reduced,' and 'independent' conveying their significance, tone of positivity, and eagerness to spread impactful clinical information.
Most discussions support the positive findings of the study, emphasizing the benefits of finerenone for patients with CKD and T2DM, often quoting trial results and highlighting no difference based on pre-existing CVD.
The discussions demonstrate high interest, with many mentions of study outcomes, benefits, and implications for treatment, using keywords like 'reduced,' 'benefits,' and 'independent of CVD status.'
Many posts reference specific findings, cite sources, and share links to full studies, reflecting deep engagement and a desire to inform or persuade.
The widespread sharing of detailed results and emphasis on the drug’s new applications suggest that these discussions could influence clinical practice and awareness among healthcare providers and patients alike.
Finerenone reduced composite of cardiovascular outcomes in patients with CKD & Type 2 Diabetes in the FIDELIO-DKD trial, with no treatment effect of pre-existing CVD. Read more: https://t.co/Ibl5Zwa26x #AHAJournals @Filippatos https://t.co/8AQazHqGPn
Finerenone and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes https://t.co/VcuK2JD0cb @Diabetes_SEMI @IcyfaSemi @chemachir @Medtorek @ana_apiecar @paomorejon @MiguelCamafort @SantasEnrique @secardiologia
FIDELIO-DKD: Among patients with CKD & T2D, finerenone reduced the incidence of the composite CV outcome, with no evidence of differences in treatment effect based on pre-existing CVD status #Cardiorenal #Nephpearls https://t.co/QFhGSsXVEn https://t.co/EWvHRmZTdJ https://t.co/e3fI5ggKZg
Check Finerenone and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes from AHA https://t.co/UnwOEWTRf9 @Stenodiabetes
Y ahora #finerenona en #DM2 con #ERC, independientemente de que tengan #ECV o no. De todo para tod@s, pero mucho bueno, además.
Finerenone and Cardiovascular Outcomes in Patients with CKD and Type II DM Assess full paper here
Stress cardiomyopathy is an acute heart failure condition recognized for serious complications such as ventricular arrhythmias. This video explores its increasing incidence, contributing risk factors, and current…
Stress cardiomyopathy is an acute heart failure condition now recognized for its serious complications. This video discusses the increasing incidence, potential triggers, and essential diagnostic and treatment…
高K血症が少ないのはいいなと思うけど Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes https://t.co/ca3Q9n1S70
Finerenone & CVS Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes. Among pt w/ CKD & T2DM, finerenone reduced incidence of the composite CVS outcome, w/ no evidence of differences in treatment effect based on preexisting CVD status https://t.co/BLkCihy5HL
RT @pinacol: 【事前指定追加解析: FIDELIO-DKD】最適なRAS阻害薬で治療されている尿中アルブミン/クレアチニン比が30-5000mg/gで25≤eGFR<75mL/min/1.73m^2の2型糖尿病患者において、Finerenoneは心血管疾患の有無にか…
New2Trip: Finerenone & Cardiovascular Outcomes in Patients w/ Chronic Kidney Disease & Type 2 Diabetes https://t.co/gHDMzMkL7O
New2Trip: Finerenone & Cardiovascular Outcomes in Patients w/ Chronic Kidney Disease & Type 2 Diabetes https://t.co/gHDMzMkL7O
New2Trip: Finerenone & Cardiovascular Outcomes in Patients w/ Chronic Kidney Disease & Type 2 Diabetes https://t.co/gHDMzMkL7O
Among patients with chronic kidney disease and type 2 diabetes, finerenone reduced incidence of the composite cardiovascular outcome. @CircAHA https://t.co/xsvgNXciBu
RT @CircAHA: Finerenone reduced composite of cardiovascular outcomes in patients with CKD & Type 2 Diabetes in the FIDELIO-DKD trial, with…
RT @CircAHA: Finerenone reduced composite of cardiovascular outcomes in patients with CKD & Type 2 Diabetes in the FIDELIO-DKD trial, with…
Finerenone reduced composite of cardiovascular outcomes in patients with CKD & Type 2 Diabetes in the FIDELIO-DKD trial, with no treatment effect of pre-existing CVD. Read more: https://t.co/Ibl5Zwa26x #AHAJournals @Filippatos https://t.co/8AQazHqGPn
RT @IGOARANBAR: Y ahora #finerenona en #DM2 con #ERC, independientemente de que tengan #ECV o no. De todo para tod@s, pero mucho bueno, ad…
Y ahora #finerenona en #DM2 con #ERC, independientemente de que tengan #ECV o no. De todo para tod@s, pero mucho bueno, además.
Finerenone and Cardiovascular Outcomes in Patients with CKD/T2DM. An analysis based on CVD status was recently published showing benefits in patients with or without CVD. https://t.co/iZeU4Tzgqw https://t.co/DIIzld28Fa
【事前指定追加解析: FIDELIO-DKD】最適なRAS阻害薬で治療されている尿中アルブミン/クレアチニン比が30-5000mg/gで25≤eGFR<75mL/min/1.73m^2の2型糖尿病患者において、Finerenoneは心血管疾患の有無にかかわらず心血管転帰（心血管死等）のリスクを減少させた。 #ペ読 https://t.co/AaodvNNn49
RT @FormigaFrancesc: Finerenone and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes https://t.co/VcuK2J…
RT @edgarvlermamd: FIDELIO-DKD: Among patients with CKD & T2D, finerenone reduced the incidence of the composite CV outcome, with no eviden…
Finerenone and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes https://t.co/IljGFUmwTS
RT @HanCardiomd: Finerenone and Cardiovascular Outcomes in Patients with CKD and Type II DM Assess full paper here
Finerenone and Cardiovascular Outcomes in Patients with CKD and Type II DM Assess full paper here
RT @P_Rossing: Check Finerenone and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes from AHA https://t.…
RT @P_Rossing: Check Finerenone and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes from AHA https://t.…
RT @P_Rossing: Check Finerenone and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes from AHA https://t.…
RT @P_Rossing: Check Finerenone and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes from AHA https://t.…
Check Finerenone and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes from AHA https://t.co/UnwOEWTRf9 @Stenodiabetes
RT @edgarvlermamd: FIDELIO-DKD: Among patients with CKD & T2D, finerenone reduced the incidence of the composite CV outcome, with no eviden…
RT @edgarvlermamd: FIDELIO-DKD: Among patients with CKD & T2D, finerenone reduced the incidence of the composite CV outcome, with no eviden…
一方、腎イベントでは交互作用p=0.016。 https://t.co/C2pk1xkVK1 https://t.co/luZpZTNoIj
RT @edgarvlermamd: FIDELIO-DKD: Among patients with CKD & T2D, finerenone reduced the incidence of the composite CV outcome, with no eviden…
RT @edgarvlermamd: FIDELIO-DKD: Among patients with CKD & T2D, finerenone reduced the incidence of the composite CV outcome, with no eviden…
FIDELIO-DKD: Among patients with CKD & T2D, finerenone reduced the incidence of the composite CV outcome, with no evidence of differences in treatment effect based on pre-existing CVD status #Cardiorenal #Nephpearls https://t.co/QFhGSsXVEn https://t.co/EWvHRmZTdJ https://t.co/e3fI5ggKZg
FIDELIO-DKD: Among patients with CKD & T2D, finerenone reduced the incidence of the composite CV outcome, with no evidence of differences in treatment effect based on pre-existing CVD status #Cardiorenal #Nephpearls https://t.co/QFhGSsXVEn https://t.co/kSX7FUCOeI https://t.co/ErBEp8Od5z
FIDELIO-DKD: Among patients with CKD & T2D, finerenone reduced incidence of the composite CV outcome, with no evidence of differences in treatment effect based on pre-existing CVD status #Cardiorenal #Nephpearls https://t.co/QFhGSsXVEn https://t.co/1baw7Mhih7
Finerenone and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes https://t.co/ueQpPQFXeJ
RT @ValleAlfonso:
RT @CircAHA: FIDELIO-DKD: Finerenone- nonsteroidal MRA - reduced CV events in patients w/CKD and T2DM, independent of CVD status #CircAHA20…
RT @FormigaFrancesc: Finerenone and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes https://t.co/VcuK2J…
Finerenone and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes https://t.co/7w8kQ3nd9t
RT @FormigaFrancesc: Finerenone and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes https://t.co/VcuK2J…
RT @FormigaFrancesc: Finerenone and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes https://t.co/VcuK2J…
Finerenone and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes https://t.co/VcuK2JD0cb @Diabetes_SEMI @IcyfaSemi @chemachir @Medtorek @ana_apiecar @paomorejon @MiguelCamafort @SantasEnrique @secardiologia
RT @CircAHA: FIDELIO-DKD: Finerenone- nonsteroidal MRA - reduced CV events in patients w/CKD and T2DM, independent of CVD status #CircAHA20…
RT @CircAHA: FIDELIO-DKD: Finerenone- nonsteroidal MRA - reduced CV events in patients w/CKD and T2DM, independent of CVD status #CircAHA20…
https://t.co/CBhryvZDBf Finerenone and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes サブ解析
RT @CircAHA: FIDELIO-DKD: Finerenone- nonsteroidal MRA - reduced CV events in patients w/CKD and T2DM, independent of CVD status #CircAHA20…
RT @CircAHA: FIDELIO-DKD: Finerenone- nonsteroidal MRA - reduced CV events in patients w/CKD and T2DM, independent of CVD status #CircAHA20…
RT @CircAHA: FIDELIO-DKD: Finerenone- nonsteroidal MRA - reduced CV events in patients w/CKD and T2DM, independent of CVD status #CircAHA20…
RT @CircAHA: FIDELIO-DKD: Finerenone- nonsteroidal MRA - reduced CV events in patients w/CKD and T2DM, independent of CVD status #CircAHA20…
RT @CircAHA: FIDELIO-DKD: Finerenone- nonsteroidal MRA - reduced CV events in patients w/CKD and T2DM, independent of CVD status #CircAHA20…
Diabetes y enfermedad renal, otra alternativa con Finerenone. https://t.co/VqJIf6lBXJ
RT @CircAHA: FIDELIO-DKD: Finerenone- nonsteroidal MRA - reduced CV events in patients w/CKD and T2DM, independent of CVD status #CircAHA20…
RT @jia_xiaoming: Composite CV risk reduction of finerenone consistent across patients with and without hx of CVD. Low incidence of hyperK…
RT @jia_xiaoming: Composite CV risk reduction of finerenone consistent across patients with and without hx of CVD. Low incidence of hyperK…
Composite CV risk reduction of finerenone consistent across patients with and without hx of CVD. Low incidence of hyperK related treatment discontinuation. Full findings published in @CircAHA. #AHA20 #CircAHA https://t.co/yFZeL6el12
Finerenone and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes https://t.co/V84ggV0gpT